Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $84

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

0.00

Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ: TARS) with a Buy and raises the price target from $78 to $84.